Duncan v. Theratx, Inc.

775 A.2d 1019, 2001 Del. LEXIS 243, 2001 WL 673698
CourtSupreme Court of Delaware
DecidedJune 1, 2001
Docket575, 2000
StatusPublished
Cited by93 cases

This text of 775 A.2d 1019 (Duncan v. Theratx, Inc.) is published on Counsel Stack Legal Research, covering Supreme Court of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Duncan v. Theratx, Inc., 775 A.2d 1019, 2001 Del. LEXIS 243, 2001 WL 673698 (Del. 2001).

Opinion

VEASEY, Chief Justice:

In this certification proceeding, we resolve a novel question of Delaware law certified to this Court by the United States Court of Appeals for the Eleventh Circuit in accordance with Article IV, Section 11(9), of the Delaware Constitution and Supreme Court Rule 41. The certified question concerns the appropriate method of calculating contract damages where an issuer’s temporary suspension of a shelf registration prevents trading by stockholders in violation of the terms of a merger agreement. Specifically, the question posed is:

What is the proper measure of damages when a defendant’s contractual obligation to cause a shelf registration, under which plaintiff is entitled to trade a restricted stock, to remain in effect for a specified period of time is breached by defendant’s temporary suspension of plaintiffs’ ability to trade the restricted stock?

We conclude that, under Delaware law, contract damages in this situation are measured by calculating the difference between (1) the highest intermediate price of the shares during a reasonable time at the beginning of the restricted period, which functions as an estimate of the price that the stockholders would have received if they had been able to sell their shares, and (2) the average market price of the shares during a reasonable period after the restrictions were lifted. This damages rule provides a suitable approximation of the damages that the stockholders incurred as a result of the breach, while allocating exclusively to the stockholders who elect to retain their shares after reinstatement of the shelf registration the risk of subsequent positive and negative share price changes.

Facts

As part of a 1994 merger between Ther-aTx, Inc. and PersonaCare, Inc., Persona-Care shareholders received restricted, un *1021 registered shares in TheraTx. 1 The merger agreement provides that Delaware law governs “the construction of its terms, and the interpretation and enforcement of the rights and duties of the parties.” Under the merger agreement, TheraTx was required to file a shelf registration, to last for two years, that would permit holders to trade these shares in the event that TheraTx elected to undertake a public offering. On June 24, 1994, TheraTx conducted an initial public offering of its shares and, in accordance with its obligations under the agreement, TheraTx filed a shelf registration for the restricted shares that became effective on December 12, 1994.

On January 13, 1995, one month after trading began in the restricted shares, TheraTx purchased Southern Management Services, Inc. Because this merger was a material change requiring an amendment to the shelf registration, the Securities and Exchange Commission advised TheraTx to suspend the shelf registration and to reimpose the trading restrictions on the shares held by the former PersonaCare stockholders. The suspension took effect on January 13, 1995 and continued until June 30, 1995. During this period, the TheraTx share price reached a high of $23/6 and then fell to $13% at the time that the shelf registration was reinstated. In March 1997, Vencor, Inc, purchased Ther-aTx in a tender offer for $17.10 per share.

James Duncan and other former Perso-naCare stockholders (collectively, “the Duncan Group”) sued TheraTx in the District Court for the Northern District of Georgia for breach of the merger agreement. The District Court found that the suspension of trading constituted a breach of the merger agreement and awarded damages equal to the highest share price during the ten day period following the suspension of trading ($19.75), reduced by the actual sale price that each plaintiff actually obtained for the shares. 2 The Eleventh Circuit agreed that TheraTx breached the agreement, but certified to this Court the above question concerning the proper method of calculating the damages from the breach.

Determining the Appropriate Measure of Damages

The question certified by the Eleventh Circuit requires us to determine the appropriate default measure of damages under Delaware law for an issuer’s breach of a merger agreement that results in a temporary restriction on certain stockholders’ ability to sell their shares. Questions certified for resolution by the Court under Supreme Court Rule 41 are determined as a matter of law on the undisputed facts submitted by the certifying court in its Certificate of Questions of Law. 3

We begin with the basic proposition that default damages rules, like other contract rules, should generally reflect the contract term that most parties would have bargained for at the time of the agreement. 4 Applying this principle to the *1022 present case, the Court must identify the damages rule that, when viewed from the time of the merger agreement, provides the stockholders with adequate compensation for a breach and provides both parties with the appropriate incentive to minimize joint losses from the breach. 5

As both parties recognize, the standard remedy for breach of contract is based upon the reasonable expectations of the parties ex ante. This principle of expectation damages is measured by the amount of money that would put the promisee in the same position as if the promisor had performed the contract. 6 Expectation damages thus require the breaching promisor to compensate the promisee for the promisee’s reasonable expectation of the value of the breached contract, and, hence, what the promisee lost.

The merger agreement in the present case entitled the Duncan Group members to trade their shares for a period of two years. Under this provision, the Duncan Group members reasonably expected to have the maximum freedom to choose when to trade their shares during this period and at what price. The breach of the merger agreement by TheraTx, however, caused this expectation to be disappointed. 7

The stockholders’ lost expectation interest in this situation is the reduction in the stockholders’ presumptive capital gains attributable to the trading restrictions. The magnitude of this reduction is, in theory, the difference between the market price of the shares at the time that the stockholders could have sold the shares in the absence of the restrictions and some measure of the value of the shares after restrictions were lifted. Because these determinations are necessarily hypothetical, the question becomes: (1) How best to estimate what *1023 the sale price would have been absent the restrictions, and (2) at what point the Court should measure the value of the shares after the restrictions are lifted. 8

Estimating the Hypothetical Sale Price Using the “Highest Intermediate Price”

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Tatum v. Fairstead Affordable LLC
Court of Chancery of Delaware, 2025
Nancy Rosado v. MidCities Auto Sales, LLC
Delaware Court of Common Pleas, 2025
Cornelius T. Walker, Jr. v. FRP Investors GP, LLC
Court of Chancery of Delaware, 2025
ITG Brands, LLC v. Reynolds American Inc.
Court of Chancery of Delaware, 2025
Givaudan v. Conagen
128 F.4th 485 (Second Circuit, 2025)
Enhabit, Inc. v. Nautic Partners IX, L.P.
Court of Chancery of Delaware, 2024
Green Cross v. Mangisi
Court of Appeals of Arizona, 2024
Sofregen Medical, Inc. v. Allergan Sales, LLC
Superior Court of Delaware, 2024
Fortis Advisors LLC v. Johnson & Johnson
Court of Chancery of Delaware, 2024
Vivint Solar, Inc. v. Jim Lundberg
Court of Chancery of Delaware, 2024
Feenix Payment Systems, LLC v. Blum
Superior Court of Delaware, 2024

Cite This Page — Counsel Stack

Bluebook (online)
775 A.2d 1019, 2001 Del. LEXIS 243, 2001 WL 673698, Counsel Stack Legal Research, https://law.counselstack.com/opinion/duncan-v-theratx-inc-del-2001.